Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 06, 2026, titled "Press Release - CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11".
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 06, 2026, titled "Press Release - CuraTeQ Biologics Announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11".